↓ Skip to main content

Dove Medical Press

Article Metrics

Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer

Overview of attention for article published in International Journal of Nanomedicine, April 2009
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#34 of 3,556)
  • High Attention Score compared to outputs of the same age (95th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news
2 news outlets
blogs
1 blog
patent
42 patents
wikipedia
2 Wikipedia pages

Citations

dimensions_citation
568 Dimensions

Readers on

mendeley
623 Mendeley
Title
Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer
Published in
International Journal of Nanomedicine, April 2009
DOI 10.2147/ijn.s3061
Pubmed ID
Authors

Silverio Tomao

Abstract

Breast cancer is the most common type of malignancy diagnosed in women. In the metastatic setting this disease is still uncurable. Taxanes represent an important class of antitumor agents which have proven to be fundamental in the treatment of advanced and early-stage breast cancer, but the clinical advances of taxanes have been limited by their highly hydrophobic molecular status. To overcome this poor water solubility, lipid-based solvents have been used as a vehicle, and new systemic formulations have been developed, mostly for paclitaxel, which are Cremophor-free and increase the circulation time of the drug. ABI-007 is a novel, albumin-bound, 130-nm particle formulation of paclitaxel, free from any kind of solvent. It has been demonstrated to be superior to an equitoxic dose of standard paclitaxel with a significantly lower incidence of toxicities in a large, international, randomized phase III trial. The availability of new drugs, such as Abraxane, in association with other traditional and non-traditional drugs (new antineoplastic agents and targeted molecules), will give the oncologist many different effective treatment options for patients in this setting.

Mendeley readers

The data shown below were compiled from readership statistics for 623 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 4 <1%
United States 3 <1%
Netherlands 2 <1%
Poland 2 <1%
Austria 1 <1%
Lithuania 1 <1%
Slovenia 1 <1%
France 1 <1%
Spain 1 <1%
Other 1 <1%
Unknown 606 97%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 144 23%
Student > Master 94 15%
Researcher 78 13%
Student > Bachelor 61 10%
Student > Doctoral Student 43 7%
Other 91 15%
Unknown 112 18%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 98 16%
Chemistry 98 16%
Agricultural and Biological Sciences 87 14%
Biochemistry, Genetics and Molecular Biology 68 11%
Medicine and Dentistry 50 8%
Other 99 16%
Unknown 123 20%

Attention Score in Context

This research output has an Altmetric Attention Score of 29. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 April 2022.
All research outputs
#1,022,880
of 21,271,011 outputs
Outputs from International Journal of Nanomedicine
#34
of 3,556 outputs
Outputs of similar age
#16,138
of 323,833 outputs
Outputs of similar age from International Journal of Nanomedicine
#1
of 47 outputs
Altmetric has tracked 21,271,011 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,556 research outputs from this source. They receive a mean Attention Score of 4.2. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 323,833 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 47 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.